Drug Resistance Research for Osteosarcoma

Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines why some bone cancers, such as osteosarcoma, respond differently to drug treatments. Researchers aim to understand why certain tumors resist treatment and how high pressure inside tumors might affect drug effectiveness. They will also analyze blood samples to find clues about tumor behavior. Individuals who have had or will have a biopsy or surgery for bone or other solid tumors might be suitable candidates for this study. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could improve future cancer treatments.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this study's methods are safe?

Research has shown that this study aims to understand how tumors respond to different drug treatments. The trial does not test new drugs on people, so no specific safety data exists for participants. Instead, the study examines tumor samples in the lab.

While there are no direct safety concerns for participants in this trial, it's important to note that it doesn't test a drug's effects on humans. Participants will provide tissue and blood samples, which are generally safe procedures with low risk.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on understanding drug resistance in osteosarcoma, a bone cancer that often affects teenagers and young adults. Unlike standard treatments such as surgery, chemotherapy, and radiation, this trial involves tissue procurement to study the cancer at a molecular level. By analyzing tumor tissues, researchers aim to uncover why some osteosarcoma cells become resistant to existing drugs. This could lead to the development of more effective, targeted therapies in the future, providing hope for patients who do not respond well to current treatment options.

What evidence suggests that this trial's treatments could be effective for osteosarcoma?

Research shows that osteosarcoma, a type of bone cancer, can sometimes stop responding to drug treatments, meaning the medicines that usually help no longer work. Studies suggest that high pressure inside tumors might be one reason for reduced drug effectiveness. In this trial, researchers will examine this pressure and other factors from tumor samples to better understand drug resistance. Although this study focuses on understanding tumors, it could lead to more effective treatments in the future.

Who Is on the Research Team?

JH

John Healey, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for individuals with a presumed or confirmed diagnosis of bone cancer (osteosarcoma) or other solid tumors who are undergoing biopsy or surgery. It's open to adults and minors; adults must consent, while minors give assent and have parental consent.

Inclusion Criteria

I have or had a biopsy or surgery for bone or solid tumor cancer diagnosis or treatment.
I am under 18 and both I and my guardian have agreed to the treatment.

Exclusion Criteria

N/A

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection

Tumor and blood samples are collected for laboratory analysis to study chemotherapy resistance and oncogenesis

1 week
1 visit (in-person)

Laboratory Analysis

Tumor samples are analyzed in vitro to determine chemotherapy resistance and correlate with clinical outcomes

4-6 weeks

Follow-up

Participants are monitored for safety and effectiveness after sample collection and analysis

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • NA
  • Tissue Procurement
Trial Overview The study aims to understand how osteogenic sarcoma and other solid tumors react to drug therapies by examining tumor tissue and blood samples. Researchers will look into why some tumors resist treatment and the impact of internal tumor pressure on drug effectiveness.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Hospital for Special Surgery, New York

Collaborator

Trials
257
Recruited
61,800+

Weill Medical College of Cornell University

Collaborator

Trials
1,103
Recruited
1,157,000+

Columbia University

Collaborator

Trials
1,529
Recruited
2,832,000+

Rockefeller University

Collaborator

Trials
162
Recruited
16,700+

Citations

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security